Core Viewpoint - The stock of药捷安康-B (02617) surged over 10%, reaching a new high of 78 HKD, driven by its inclusion in the Hong Kong Stock Connect program and the progress of its clinical trials for its core product, Tinengotinib [1] Group 1: Stock Performance -药捷安康-B's stock increased by 10.14%, trading at 69.5 HKD with a transaction volume of 32.81 million HKD [1] Group 2: Market Announcement - The Shanghai Stock Exchange and Shenzhen Stock Exchange announced that药捷安康 has been added to the Hong Kong Stock Connect eligible list, effective from September 8 [1] Group 3: Clinical Development - The company announced the completion of the first patient dosing in an open-label, multicenter Phase II clinical study for its core product, Tinengotinib, in combination with 康方生物科技's 开坦尼 and 依达方 for the treatment of advanced hepatocellular carcinoma [1]

Core Viewpoint - The stock of ZhiJie AnKang-B (02617) has surged over 10%, reaching a new high of 78 HKD, driven by its inclusion in the Hong Kong Stock Connect program and the progress of its clinical trials for its core product, Tinengotinib [1] Group 1: Stock Performance - ZhiJie AnKang-B's stock increased by 10.14%, trading at 69.5 HKD with a transaction volume of 32.81 million HKD [1] Group 2: Market Announcement - The Shanghai Stock Exchange and Shenzhen Stock Exchange announced that ZhiJie AnKang has been added to the Hong Kong Stock Connect eligible list, effective from September 8 [1] Group 3: Clinical Development - ZhiJie AnKang has completed the first patient dosing in a Phase II clinical study for its core product, Tinengotinib, in combination with Canfite BioPharma's treatments for advanced hepatocellular carcinoma [1]

Core Viewpoint - The stock of the company,药捷安康-B (02617), has seen a significant increase, reaching a new high of 64.8 HKD, nearly quadrupling from its IPO price of 13.15 HKD, indicating strong market performance and investor interest [1] Group 1: Stock Performance - The stock price increased by over 8% during trading, peaking at 64.8 HKD, and is currently up 5.26% at 63 HKD with a trading volume of 11.809 million HKD [1] - The stock has appreciated nearly four times since its initial public offering [1] Group 2: Clinical Research - The company announced the completion of the first patient dosing in a Phase II clinical study for its core product,替恩戈替尼, in combination with 康方生物's 开坦尼 and 依达方 for the treatment of advanced hepatocellular carcinoma [1] - The study aims to evaluate the safety and efficacy of the combination therapy, targeting patients who have not previously received systemic anti-tumor therapy or have failed standard treatment for advanced hepatocellular carcinoma [1] Group 3: Index Inclusion - On August 22, the Hang Seng Index Company announced that the company will be included in the Hang Seng Composite Index, with changes effective after market close on September 5 and active from September 8 [1] - According to Huatai Securities, the company may be included in the Hong Kong Stock Connect due to meeting various criteria including market capitalization, liquidity, and listing duration [1]

Group 1 - The core product of the company, Tiengogatinib, has completed the first patient dosing in a Phase II clinical study for the treatment of advanced hepatocellular carcinoma in combination with Kangfang Biotech's Ketanib and Idafos. The study aims to evaluate the safety and efficacy of the combination therapy for patients who have not received systemic anti-tumor therapy or have failed standard treatment for advanced liver cancer [1] - The stock price of the company surged over 8%, reaching a new high of 64.8 HKD, which is nearly four times the IPO price of 13.15 HKD. As of the latest update, the stock is trading at 63 HKD with a transaction volume of 11.809 million HKD [1] - The company has been included in the Hang Seng Composite Index, with the changes set to take effect after the market closes on September 5 and will be effective from September 8. This inclusion may lead to adjustments in the eligible stocks for the Hong Kong Stock Connect, as the company meets various criteria including market capitalization, liquidity, and listing duration [1]

Core Viewpoint - The company has completed the first patient dosing in a Phase II clinical trial evaluating the combination of Tinengotinib with Kanfang Biotech's anti-cancer drugs for advanced hepatocellular carcinoma [1][2] Group 1: Clinical Trial Details - The trial is an open-label, multicenter Phase II study conducted in China, aimed at assessing the efficacy and safety of Tinengotinib in combination with Kanfang's drugs, Kadyuoni (PD-1/CTLA-4) and Yidafang (PD-1/VEGF) [2] - The primary objective of the trial is to evaluate the safety and effectiveness of the combination therapies compared to Tinengotinib monotherapy in patients with advanced hepatocellular carcinoma who have not received prior systemic anti-tumor treatment or have failed standard treatment [2] Group 2: Collaboration and Development - The company has established a collaboration agreement with Kanfang Biotech to jointly develop clinical combination therapies in the field of hepatocellular carcinoma [2]

Core Viewpoint - The company announced the completion of the first patient dosing in a Phase II clinical trial evaluating the efficacy and safety of Tinengotinib in combination with other therapies for advanced hepatocellular carcinoma [1] Group 1: Clinical Trial Details - The trial is an open-label, multicenter Phase II study conducted in China [1] - It aims to assess the safety and efficacy of Tinengotinib combined with Kantonib (PD-1/CTLA-4) and Yidafang (PD-1/VEGF) in treating advanced hepatocellular carcinoma [1] - The primary target population includes patients who have not previously received systemic anti-tumor treatment for hepatocellular carcinoma or those who have failed standard treatment [1] Group 2: Collaboration - The company has established a collaboration agreement with Kanton Biotechnology to jointly develop clinical combination therapies in the field of hepatocellular carcinoma [1]

Core Viewpoint - The company announced the initiation of a Phase II clinical trial for its core product, Tinengotinib (TT-00420), in combination with other therapies for the treatment of advanced hepatocellular carcinoma (HCC) [1] Group 1: Clinical Trial Details - The trial is an open-label, multicenter Phase II study conducted in China [1] - The primary objective is to evaluate the safety and efficacy of Tinengotinib in combination with Kanfar Biotech's Katanib (PD-1/CTLA-4) and Yida Pharma's Yivofisi (PD-1/VEGF) [1] - The target population includes patients with advanced HCC who have not previously received systemic anti-tumor therapy or have failed standard treatment [1] Group 2: Collaboration and Development - The company has entered into a collaboration agreement with Kanfar Biotech to jointly develop clinical combination therapies in the field of hepatocellular carcinoma [1]

Core Viewpoint - The company announced the completion of the first patient dosing in a Phase II clinical trial evaluating the efficacy and safety of Tinengotinib in combination with other therapies for advanced hepatocellular carcinoma [1] Group 1: Clinical Trial Details - The trial is an open-label, multicenter Phase II study conducted in China [1] - It aims to assess the safety and efficacy of Tinengotinib combined with either Kantonib (PD-1/CTLA-4) or Yidafang (PD-1/VEGF) in treating advanced hepatocellular carcinoma [1] - The primary target population includes patients who have not previously received systemic anti-tumor treatment for hepatocellular carcinoma or those who have failed standard treatment [1] Group 2: Collaboration - The company has established a collaboration agreement with Kangfang Biotechnology to jointly develop clinical combination therapies in the field of hepatocellular carcinoma [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 TransThera Sciences (Nanjing), Inc. 藥捷安康（南京）科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 本試驗為在中國開展的一項評價開坦尼®(卡度尼利，PD-1/CTLA-4)╱依達方®(依 沃西，PD-1/VEGF)聯合替恩戈替尼片治療晚期肝細胞癌療效和安全性的開放性、 多中心、II期臨床研究，試驗的主要目標為評估開坦尼®(卡度尼利，PD-1/CTLA- 4)╱依達方®(依沃西，PD-1/VEGF)分別聯合替恩戈替尼片或替恩戈替尼單藥治療 晚期肝細胞癌的安全性和有效性。該試驗的主要目標人群為既往未接受過針對肝 細胞癌的全身抗腫瘤治療或既往標準治療失敗後的晚期肝細胞癌患者。 藥捷安康已與康方生物訂立合作協議，雙方共同針對肝細胞癌領域開展臨床聯合 用藥開發。 1 （股份代號：2617） 自願性公告 替恩戈替尼聯用康方生物開坦尼®(卡度尼利，PD-1/CTLA- ...

Core Viewpoint - The Hong Kong IPO market is active, with 57 new listings and a total fundraising amount of 131.9 billion HKD as of August 25. However, many companies face challenges in meeting both domestic and Hong Kong regulatory requirements for listing [1]. Group 1: Hong Kong IPO Overview - As of August 25, 2023, there have been 57 new IPOs on the Hong Kong Stock Exchange, raising a total of 131.9 billion HKD [1]. - There are currently 211 companies that have submitted applications for listing in Hong Kong [1]. Group 2: Listing Challenges - Companies looking to list in Hong Kong must comply with both domestic laws and Hong Kong's regulatory framework, making the IPO preparation process complex and demanding [1]. Group 3: Resources for Companies - A compilation of Hong Kong listing rules and disclosure documents for domestic companies planning to list in Hong Kong has been organized to assist businesses in understanding the latest regulatory dynamics [1].